CANCER RESEARCH UK LBG

Their core work

Cancer Research UK is the UK's largest charity dedicated to cancer research, funding thousands of scientists and clinical trials across the country. Within H2020, their participation focused on fundamental cancer biology — particularly DNA repair mechanisms, replication dynamics, and dendritic cell immunology — through Marie Skłodowska-Curie fellowships and training networks. They serve as a host institution for early-career researchers working on molecular-level questions that underpin future cancer therapies. Their work bridges basic molecular biology with translational oncology, as evidenced by their involvement in the TransPot prostate cancer network.

What they specialise in

How they've shifted over time

Cancer Research UK's H2020 activity was concentrated in a narrow window (2015-2017), with most projects focused on fundamental molecular biology — DNA repair pathways, replication machinery, and gene regulation. Their later involvement shifted toward translational medicine through TransPot (2017-2021), a prostate cancer network bridging lab findings and clinical application. This suggests a trajectory from hosting basic science fellowships toward participating in disease-focused translational consortia.

Their move from basic molecular biology fellowships toward translational disease-specific networks suggests future H2020/Horizon Europe involvement will likely center on clinical translation and multi-site cancer research consortia.

How they like to work

Cancer Research UK never coordinated an H2020 project — they participated as a host institution for MSCA fellows and as a partner in training networks. With 17 unique partners across 6 countries from just 5 projects, they connect broadly rather than deeply with any single partner. This profile suggests they function as a prestigious research host that attracts international talent rather than as a consortium-building lead.

Collaborated with 17 distinct partners across 6 countries, indicating a moderately broad European network built primarily through MSCA mobility programmes. Their London base and charity status make them a natural magnet for international postdoctoral researchers.

What sets them apart

Cancer Research UK is not a university or public research institute — it is the UK's largest independent cancer research funder and operator, giving it unique access to research infrastructure, patient data pipelines, and clinical trial networks that most academic partners cannot match. For consortium builders, partnering with CR-UK means access to one of Europe's deepest cancer research ecosystems, including affiliated labs across major UK hospitals and universities. Their MSCA hosting record shows they can attract and support top early-career talent in molecular oncology.

Highlights from their portfolio

• BRCA2Interact
  Directly addresses BRCA2-RAD51 repair complexes — a pathway central to hereditary breast/ovarian cancer and PARP inhibitor drug development.
• TransPot
  Their only training network and longest project (2017-2021), signaling a shift toward translational, multi-partner cancer research.
• SMI REP
  Single-molecule level investigation of DNA replication — represents advanced biophysics capability not common among cancer charities.